MedTrace Logo

Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract

NCT00003334 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-03-11

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and paclitaxel in treating patients who have recurrent or refractory endometrial cancer, fallopian tube cancer, or sarcoma of the female reproductive tract.

Conditions

Interventions

DRUG

paclitaxel

DRUG

pegylated liposomal doxorubicin hydrochloride

Sponsors & Collaborators

Principal Investigators

  • Franco M. Muggia, MD · NYU Langone Health

Study Design

Purpose
TREATMENT

Eligibility

Max Age
120 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-03-31
Primary Completion
2001-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003334 on ClinicalTrials.gov